Induced expression of p16(INK4α) inhibits both CDK4- and CDK2- associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes

Molecular and Cellular Biology

Volumn 19, Issue 3, 1999, Pages 1981-1989

  McConnell, Beth B ^a,b   Gregory, Fiona J ^a   Stott, Francesca J ^a   Hara, Eiji ^a,c   Peters, Gordon ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P16;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITOR INTERACTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0032981481     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/mcb.19.3.1981     Document Type: Article

References (78)

1. INK4d, a specific inhibitor of cyclin D-dependent kinases. Blood 90:126-137.
2. Alcorta, D. A., Y. Xiong, D. Phelps, G. Hannon, D. Beach, and J. C. Barrett. 1996. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence. Proc. Natl. Acad. Sci. USA 93:13742-13747.
3. Bartkova, J., M. Zemanova, and J. Bartek. 1996. Abundance and subcellular localisation of cyclin D3 in human tumours. Int. J. Cancer 65:323-327.
4. Bates, S., L. Bonetta, D. MacAllan, D. Parry, A. Holder, C. Dickson, and G. Peters. 1994. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 9:71-79.
5. KIP1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J. Biol. Chem. 272:25863-25872.
6. INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4. Mol. Cell 1:421-431.
7. ink4. Mol. Cell. Biol. 15:2682-2688.
8. CIPI. Mol. Cell. Biol. 16: 4673-4682.
9. Dai, K., R. Kobayashi, and D. Beach. 1996. Physical interaction of mammalian CDC37 with CDK4. J. Biol. Chem. 271:22030-22034.
10. INK4-and p18-containing complexes in human cell lines. J. Biol. Chem. 271:15942-15949.
11. Diller, L., J. Kassel, C. E. Nelson, M. A. Gryka, G. Litwak, M. Gebhardt, B. Bressac, M. Ozturk, S. J. Baker, B. Vogelstein, and S. H. Friend. 1990. p53 functions as a cell cycle control point in osteosarcoma. Mol. Cell. Biol. 10: 5772-5781.
12. Dimri, G. P., X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E. E. Medrano, M. Linskens, I. Rubelj, O. Pereira-Smith, M. Peacocke, and J. Campisi. 1995. A novel biomarker identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92:9363-9367.
13. 1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes. Proc. Natl. Acad. Sci. USA 90:11034-11038.
14. Elledge, S. J., J. Winston, and J. W. Harper. 1996. A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Cell Biol. 6:388-392.
15. Ewen, M. E., H. K. Sluss, C. J. Sherr, H. Matsushime, J. Kato, and D. M. Livingston. 1993. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487-497.
16. Fotedar, R., P. Fitzgerald, T. Rousselle, D. Cannella, M. Dorée, H. Messier, and A. Fotedar. 1996. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene 12: 2155-2164.
17. Cip1 cyclin-dependent kinase inhibitor. Oncogene 10:2281-2287.
18. INK4/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8:2939-2952.
19. INK4d, a p16-related inhibitor specific to CDK4 and CDK6. Mol. Biol. Cell 7:57-70.
20. Hall, M., S. Bates, and G. Peters. 1995. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11:1581-1588.
21. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261.
22. CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16:859-867.
23. Harlow, E., and D. Lane. 1988. Antibodies. A laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
24. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
25. Harper, J. W., S. J. Elledge, K. Keyomarsi, B. Dynlacht, L.-H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, M. P. Fox, and N. Wei. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6:387-400.
26. 1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev. 8:1759-1771.
27. Higashi, H., I. Suzuki-Takahashi, S. Saitoh, K. Segawa, Y. Taya, A. Okuyama, S. Nishimura, and M. Kitagawa. 1996. Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin H. Eur. J. Biochem. 237:460-467.
28. Hirai, H., M. F. Roussel, J.-Y. Kato, R. A. Ashmun, and C. J. Sherr. 1995. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15:2672-2681.
29. Jen, J., J. W. Harper, S. H. Bigner, D. D. Bigner, N. Papadopoulos, S. Markowitz, J. K. V. Willson, K. W. Kinzler, and B. Vogelstein. 1994. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54:6353-6358.
30. INK4a-mediated growth suppression. Mol. Cell. Biol. 18: 5284-5290.
31. Kitagawa, M., H. Higashi, H.-K. Jung, I. Suzuki-Takahashi, M. Ikeda, K. Tamai, J. Kato, K. Segawa, E. Yoshida, S. Nishimura, and Y. Taya. 1996. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 15:7060-7069.
32. Koh, J., G. H. Enders, B. D. Dynlacht, and E. Harlow. 1995. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506-510.
33. LaBaer, J., M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847-862.
34. Lamphere, L., F. Fiore, X. Xu, L. Brizuela, S. Keezer, C. Sardet, G. F. Draetta, and J. Gyuris. 1997. Interaction between Cdc37 and Cdk4 in human cells. Oncogene 14:1999-2004.
35. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9:639-649.
36. WAF-1 gene activities. Mol. Cell. Biol. 16:1786-1793.
37. INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Oncogene 13:561-568.
38. Ink4d. Nature 389:999-1003.
39. Lukas, J., J. Bartkova, M. Welcker, O. W. Petersen, G. Peters, M. Strauss, and J. Bartek. 1995. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 10:2125-2134.
40. Lukas, J., D. Parry, L. Aagaard, D. J. Mann, J. Bartkova, M. Strauss, G. Peters, and J. Bartek. 1995. Retinoblastoma-protein-dependent cell cycle inhibition by the tumour suppressor p16. Nature 375:503-506.
41. Lundberg, A. S., and R. A. Weinberg. 1998. Functional inactivation of the retinobalstoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. 18:753-761.
42. Mahony, D., D. A. Parry, and E. Lees. 1998. Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells. Oncogene 16:603-611.
43. CIPI Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9:650-662.
44. Matsushime, H., D. E. Quelle, S. A. Shurtleff, M. Shibuya, C. J. Sherr, and J.-Y. Kato. 1994. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14:2066-2076.
45. McConnell, B. B., M. Starborg, S. Brookes, and G. Peters. 1998. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr. Biol. 8:351-354.
46. INK4a. Nat. Struct. Biol. 5:85-88.
47. INK4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. USA 92:6289-6293.
48. 1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol. 14:2077-2086.
49. Musgrove, E. A., A. Swarbrick, C. S. L. Lee, A. L. Cornish, and R. L. Sutherland. 1998. Mechanism of cyclin-dependent kinase inactivation by progestins. Mol. Cell. Biol. 18:1812-1825.
50. Sdil:CIPI:WAFI. EMBO J. 14:555-563.
51. INK4 in human cancer. Proc. Natl. Acad. Sci. USA 91:11045-11049.
52. INK4:MTSI tumour suppressor gene product. EMBO J. 14:503-511.
53. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
54. Poon, R. Y. C., H. Toyoshima, and T. Hunter. 1995. Redistribution of the CDK inhihitor p27 between different cyclin-CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol. Biol. Cell 6:1197-1213.
55. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 11:492-503.
56. Reynisdóttir, I., K. Polyak, A. Iavarone, and J. Massagué. 1995. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9:1831-1845.
57. Reznikoff, C. A., T. R. Yeager, C. A. Belair, E. Savelieva, J. A. Puthenveettil, and W. M. Stadler. 1996. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus I6 E6, but not E7, transformed human uroepithelial cells. Cancer Res. 56:2886-2890.
58. INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta Rev. Cancer 1378:115-177.
59. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382:325-331.
60. INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol. Cell. Biol. 17:2458-2467.
61. INK4. Science 267:249-252.
62. Serrano, M., G. J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
63. INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 55:6200-6209.
64. Sherr, C. J. 1996. Cancer cell cycles. Science 274:1672-1677.
65. 1 cyclin-dependent kinases. Genes Dev. 9:1149-1163.
66. Soos, T. J., H. Kiyokawa, J. S. Yan, M. S. Rubin, A. Giordano, A. DeBlasio, S. Bottega, B. Wong, J. Mendelsohn, and A. Koff. 1996. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ. 7: 135-146.
67. 1 cyclin-cdk complexes. EMBO J. 14:4814-4826.
68. Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 10:1491-1502.
69. Stone, S., P. Dayanath, P. Jiang, J. M. Weaver-Feldhaus, S. V. Tavtigian, L. Cannon-Albright, and A. Kamb. 1995. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene 11:987-991.
70. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
71. Toyoshima, H., and T. Hunter. 1994. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78:67-74.
72. INK4A. Oncogene 15:505-514.
73. INK4 mutations. Nat. Struct. Biol. 5:74-81.
74. CIPI in spontaneously immortalized human fibroblasts. Cell Growth Differ. 9:139-146.
75. Wong, H., and K. Riabowol. 1996. Differential CDK-inhibitor gene expression in aging human diploid fibroblasts. Exp. Gerentol. 31:311-325.
76. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
77. Xiong, Y., H. Zhang, and D. Beach. 1992. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505-514.
78. Zhang, H., Y. Xiong, and D. Beach. 1993. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol. Biol. Cell 4:897-906.